Tharimmune Advances Key Therapeutics Against Weaponized Fentanyl and Inflammation

Tharimmune, Inc. has issued a corporate update detailing the strides made in its therapeutic pipeline. This update highlights TH104's development as a pivotal national security measure against weaponized fentanyl and the progress in oral antibody delivery with TH023. In 2025, the company secured $5.47 million through equity financing. The funding promises to accelerate TH104's development and reinforce Tharimmune's corporate structure.

TH104 is positioned as a crucial response to high-potency opioid threats, underscored by favorable FDA feedback on its regulatory path for national security applications. TH023, focusing on oral antibody delivery for inflammation, shows promising preclinical results with potential to transform treatment protocols.

Tharimmune's reinforced leadership team, including expert James Gordon Liddy, further supports its ambitions. The company remains dedicated to innovation in therapeutics targeting critical medical needs.